The latest peer-reviewed studies, federal research milestones, and AKA statements on the science, in one feed. Every entry links to a primary source.
Records identify the products as "Smax" Pseudo-DHM tablets, a synthetic MGM-15 product now in Schedule I. AKA holds an Oxford press conference Sept. 30 at 10 a.m. CT.
American Kratom Association
Read the full release (PDF) ↗AKA asks the Lafayette County Sheriff to identify the products, distinguish natural kratom from synthetic opioids, and disclose testing status.
American Kratom Association
Read the full release (PDF) ↗AKA urges Congress to pass S. 5383 and H.R. 10272 to remove synthetic 7-OH, pseudo, MGM-15 and MGM-16 products from store shelves.
American Kratom Association
Read the full release (PDF) ↗Delaware becomes the 22nd state to enact the Kratom Consumer Protection Act.
americankratom.org/news
HB 1628 bans synthetic derivatives while establishing safeguards for natural kratom.
americankratom.org/news
AKA asks a federal court to protect natural kratom consumers from unintended Schedule I consequences of trace MGPI in botanical kratom.
americankratom.org/news
Rutgers-led preclinical study finds mitragynine reduced meth-seeking in rats without reducing motivation for food. Published in Psychopharmacology.
Rutgers Addiction Research Center
AKA challenges how DEA's temporary scheduling order is being applied to natural kratom.
americankratom.org/releases
AKA endorses DEA action on chemically manipulated compounds distinct from kratom.
americankratom.org/releases
Overdose incidents involving a mislabeled product show enforcement gaps that existing law already covers.
americankratom.org/releases
The HHS Request for Information seeks scientific evidence, not testimonials, as 7-OH manufacturers press consumers to flood the federal docket.
americankratom.org/news
DEA's action validates the distinction between the natural botanical and synthetic 7-OH products.
americankratom.org/news
Florida's Attorney General moves against 7-OH products sold as kratom.
americankratom.org/news
AKA statement on FDA's IND clearance for the first Phase I human trial of purified mitragynine for opioid use disorder.
americankratom.org/news
Randomized, double-blind, placebo-controlled Phase I trial of purified mitragynine, developed by NIH and the University of Florida under the HEAL Initiative.
nih.gov
AKA applauds Governor Walz and the Minnesota Legislature.
americankratom.org/news
Warning about dangerous 7-OH products misleadingly marketed as kratom.
americankratom.org/news
An expert forum's published conclusions on the nature and severity of kratom withdrawal.
americankratom.org/releases
HHS and FDA recommend Schedule I for chemically manipulated 7-OH; AKA supports the recommendation.
americankratom.org/news
Grundmann et al., Journal of Psychoactive Drugs: 1,049 current consumers among 11,545 respondents.
Journal of Psychoactive Drugs
FDA concludes "kratom appears well tolerated at all dose levels."
americankratom.org/news
Henningfield et al., Frontiers in Psychiatry: abuse potential does not warrant scheduling.
Frontiers in Psychiatry
91% use for pain; under 3% meet criteria for moderate or severe use disorder.
Johns Hopkins Medicine
